Biologic products, including proteins, monoclonal antibodies, vaccines, and nucleic-acid–based therapeutics, represent an advanced class of pharmaceuticals characterized by structural complexity and sensitivity to environmental conditions. Ensuring the stability of these biomolecules is critical for maintaining product safety, efficacy, and overall quality throughout their lifecycle. Conventional stability testing approaches are often time-consuming and experimentally intensive, creating a need for innovative predictive strategies. Artificial intelligence (AI) has emerged as a transformative tool capable of reshaping stability assessment and development of biologic products. AI techniques, particularly machine learning (ML) and deep learning (DL), enable the integration and analysis of large multidimensional datasets to identify degradation patterns, predict shelf life, and support formulation optimization. Advanced computational models, including structure prediction platforms such as AlphaFold and de novo design methodologies, facilitate improved understanding of protein folding, molecular interactions, and conformational stability, thereby supporting rational biologic development.AI-driven models further evaluate critical factors influencing biologic stability, including formulation composition, excipient compatibility, processing conditions, and environmental variables such as temperature, pH, light exposure, and storage stress. These predictive capabilities allow early identification of stability risks and enable data-guided decision-making during product development and manufacturing. Overall, AI demonstrates significant potential to transform biologic stability studies by accelerating development timelines, reducing experimental burden, and improving predictive accuracy. The integration of AI-based analytical frameworks into biologic development pipelines is expected to enhance product quality assurance and support future regulatory and pharmaceutical innovation.